Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lulizumab or BMS-986142 in Primary Sjögren's Syndrome
NCT02843659Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Antibody Fragments, Monoclonal Antibodies, Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Lulizumab, BMS-986142 and Placebo (3 arms). Primary endpoint: Mean Change From Baseline in ESSDAI at 12 weeks. Started Oct 2016; status: terminated.
02
Drugs
lulizumab pegolBMS-986142
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02843659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843659.